Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ICCMBullishCorporate Developmentsnews

High materiality7/10

IceCure secures IRB approval to begin ChoICE study for ProSense Cryoablation

Aug 20, 2026, 8:13 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

IRB approval and imminent enrollment are clear near-term catalysts; successful ChoICE data could improve market credibility and ongoing adoption, potentially supporting multiple expansion in physician adoption and modest revenue upside over the next 6-12 months.

AI summary

What happened, with direct paths to the underlying reporting

IceCure obtained IRB approval to begin the ChoICE post-marketing study for ProSense cryoablation in low-risk breast cancer, with enrollment expected soon. ProSense is FDA-cleared for 70+ patients with tumors ≤1.5 cm, and ICE3 showed low recurrence and high cosmetic satisfaction, supporting broader real-world adoption across 400 patients at 30 sites.

IRB approval enables ChoICE post-marketing study enrollment for ProSense.
ProSense is FDA-cleared for 70+ with tumors ≤1.5 cm; ChoICE targets 400 patients across 30 sites.
ICE3 results show 3.1% local recurrence; 99.1% patient satisfaction; 97% physician satisfaction.
Enrollment expected in coming weeks; site led by Dr. Richard Gilmore.
30 sites will serve as both study centers and commercial sites, expanding access.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.